PI
APLS

PEAK6 Investments’s Apellis Pharmaceuticals APLS Stock Holding History

PEAK6 Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,000
Closed -$118K – 3520
2024
Q1 		$118K Sell
2,000
-15,500
-89% -$988K ﹤0.01% 3312
2023
Q4 		$1.05M Sell
17,500
-31,400
-64% -$1.59M ﹤0.01% 2057
2023
Q3 		$1.86M Buy
48,900
+47,000
+2,474% +$2.06M 0.01% 1384
2023
Q2 		$173K Sell
1,900
-21,900
-92% -$1.89M ﹤0.01% 2963
2023
Q1 		$1.57M Buy
+23,800
New +$1.37M 0.01% 1501
2022
Q4 		– Sell
-58,500
Closed -$4M – 4385
2022
Q3 		$4M Buy
58,500
+56,600
+2,979% +$3.35M 0.02% 977
2022
Q2 		$173K Buy
+1,900
New +$86.6K ﹤0.01% 4875

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's APLS Position: Q2 2024 in Review

PEAK6 Investments sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 8,562 shares — an estimated $503K sold.

PEAK6 Investments first reported a position in APLS in Q2 2022 and held it in 3 quarters. The position peaked at $503K in Q1 2024. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • PEAK6 Investments reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • PEAK6 Investments sold 8,562 Apellis Pharmaceuticals shares in Q2 2024, an estimated $503K.
  • PEAK6 Investments first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • PEAK6 Investments's Apellis Pharmaceuticals position peaked at $503K in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on PEAK6 Investments's 13F filing for Q2 2024, filed 14 Aug 2024.